Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 05, 2015 9:40 AM ET


Company Overview of Symphogen A/S

Company Overview

Symphogen A/S is a biopharmaceutical company that develops recombinant antibody mixture therapeutics to improve the treatment of cancer. It develops Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor for patients with metastatic colorectal cancer and non-small cell lung cancer; Sym009, an antibody program against undisclosed infectious diseases; Sym013, a pre-clinical oncology pipeline product; and Sym015, a multi targeting mAb mixture program against the receptor tyrosine kinase c-MET. The company was founded in 2000 and is headquartered in Ballerup, Denmark.

Pederstrupvej 93

Ballerup,  2750


Founded in 2000


45 45 26 50 50


45 45 26 50 60

Key Executives for Symphogen A/S

Co-Founder, Chief Executive Officer and Director
Age: 59
Chief Financial Officer
Age: 46
Chief Scientific Officer, Medical Officer, Head of Global R&D and Co-Chairman Scientific Advisory Board
Age: 63
Chief Business Officer
Age: 60
Chief Manufacturing Officer
Compensation as of Fiscal Year 2015.

Symphogen A/S Key Developments

Symphogen Opens a Clinical Development Unit in New Jersey, US; Esper Boel Joins the Company as Chief Technology Officer

Symphogen announced that Symphogen Inc. is opening a Clinical Development Unit in New Jersey, US, under the leadership of Head of Corporate R&D, Chief Medical & Scientific Officer Dr. Ivan Horak. Additionally, Dr. Esper Boel has joined the company as Chief Technology Officer to lead Symphogen's antibody discovery activities in Denmark, including Immuno-Oncology projects. Prior to joining Symphogen, Dr. Boel served as Corporate Vice President for the Biotechnology unit in Novo Nordisk's international R&D organization. Dr. Boel has extensive experience in biopharmaceutical R&D management, and has served as Board member/consultant for high-profile antibody based companies including Xencor Inc. and Innate Pharma SA.

Symphogen Relocates to New Headquarters; Names Mads Laustsen to Chief Manufacturing Officer, Effective June 1,2014

Symphogen A/S announced the relocation of its corporate headquarters in Lyngby, outside Copenhagen, Denmark, to a 10,000 m(2) (100,000 ft(2)) facility in Ballerup, also a suburb of Copenhagen. Separately, Symphogen announced that Mads Laustsen was appointed to the newly created position of Chief Manufacturing Officer. Mads Laustsen, one of the founders of CMC Biologics, served as the company's CEO from the time of the company's inception 2001 until May 2011, when he was named to the Board of Directors. During this period, the company grew from a business idea to a global leader in contract biologics manufacturing. Laustsen joins Symphogen June 1, but remains a non-executive Director on the CMC Biologics Board. Prior to establishing CMC Biologics, he spent 16 years developing and manufacturing bulk enzymes and biopharmaceuticals at Novo Nordisk, Zymogenetics, and Novozymes. Laustsen has served as a member of various advisory boards, has been active in development of new process technologies, and holds numerous patents in the field.

Symphogen A/S Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 09:00 AM

Symphogen A/S Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 09:00 AM. Venue: OVAL Lingotto, Turin, Italy. Speakers: Jette Asboe Lassen, Director of Business Development.

Similar Private Companies By Industry

Company Name Region
Statens Serum Institut Europe
Samplix ApS Europe
Origo Biotech ApS Europe
Cantion A/S Europe
Cytoguide ApS Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Symphogen A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at